// App-Quantinova.ai

: SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy.

Researchers

Presenter

  • Sarah P. Psutka

Principal Investigators

  • Christopher Cutie

  • Sumeet Kaur Bhanvadia

  • Kirk A. Keegan

  • Wendy Crist

  • Shaozhou Ken Tian

  • John Maffeo

  • Bradley Raybold

  • Marietta Kashmer

  • Mohamad Hasan

  • Xiang Li

  • Neil Beeharry

  • Shibu Thomas

  • Hui Tian

  • Thomas Powles

Medical Centers

  • Barts Heart Centre, London, UK

  • Janssen Research and Development, LLC, Spring House, PA

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cohort

Phase

  • II

Study Id's

  • NCT04919512

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved